These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1394200)

  • 1. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.
    Nichols PH; Ramsden CW; Ward U; Sedman PC; Primrose JN
    Cancer Res; 1992 Oct; 52(20):5765-9. PubMed ID: 1394200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
    Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
    Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 treatment in colorectal cancer: current results and future prospects.
    Heys SD; Deehan DJ; Eremin O
    Eur J Surg Oncol; 1994 Dec; 20(6):622-9. PubMed ID: 7995410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peri-operative modulation of cellular immunity in patients with colorectal cancer.
    Nichols PH; Ramsden CW; Ward U; Trejdosiewicz LK; Ambrose NS; Primrose JN
    Clin Exp Immunol; 1993 Oct; 94(1):4-10. PubMed ID: 8403515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
    Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
    J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
    Jost LM; Gmür J; Oelz O; Sauter C; Stahel RA
    Schweiz Med Wochenschr; 1988 Feb; 119(5):137-43. PubMed ID: 3266369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
    Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer.
    Matsuda A; Furukawa K; Takasaki H; Suzuki H; Kan H; Tsuruta H; Shinji S; Tajiri T
    Dis Colon Rectum; 2006 Apr; 49(4):507-16. PubMed ID: 16421661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interleukin-2: a biological response modifier.
    Kintzel PE; Calis KA
    Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study.
    Wichmann MW; Hüttl TP; Winter H; Spelsberg F; Angele MK; Heiss MM; Jauch KW
    Arch Surg; 2005 Jul; 140(7):692-7. PubMed ID: 16027336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.